Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Components of Segment Revenues and Adjusted EBITDA

Segment revenues and Adjusted EBITDA consisted of the following:

	Three Months Ended March 31,
	2023						2022
				Segment						Segment
	Segment			Adjusted			Segment			Adjusted
	Revenues			EBITDA			Revenues			EBITDA(3)
Assessment, Permitting and Response	$	52,214		$	14,266		$	45,600		$	9,623
Measurement and Analysis		42,527	(1)		6,387			39,761	(1)		6,322		(2)
Remediation and Reuse		36,687			5,278			49,319			7,993
Total Operating Segments		131,428			25,931			134,680			23,938
Corporate and Other		—			(9,328	)		—			(7,487	)
Total	$	131,428		$	16,603		$	134,680		$	16,451

_____________________________________

(1) Includes revenue of $1.4 million and $5.6 million from the Discontinuing Specialty Lab, for the three months ended March 31, 2023 and March 31, 2022, respectively.
(2) Includes Adjusted EBITDA of $1.3 million from the Discontinuing Specialty Lab.

(3) Includes the add back of start-up losses and investment in new services of $0.8 million.

Reconciliation of Segment Measure to Net Loss

Presented below is a reconciliation of the Company’s segment measure to net loss:

	For the Three Months Ended March 31,
	2023				2022
Total	$	16,603			$	16,451
Interest expense, net		(1,541	)			(1,092	)
Income tax expense		(1,367	)			(1,269	)
Depreciation and amortization		(10,555	)			(12,144	)
Stock-based compensation		(13,035	)			(10,425	)
Start-up losses and investment in new services		—				(786	)
Acquisition costs		(775	)			(467	)
Fair value changes in financial instruments		(1,873	)			2,449
Fair value changes in business acquisition    contingencies		398				21
Expenses related to financing transactions		(4	)			(7	)
Discontinuing Specialty Lab		(2,436	)	(1)		—
Other losses or expenses		(134	)			(267	)
Net loss	$	(14,719	)		$	(7,536	)

__________________________

(1) Amounts consist of operating losses before depreciation related to the Discontinuing Specialty Lab.